Seer, Inc. (SEER)

NASDAQ: SEER · IEX Real-Time Price · USD
1.900
-0.040 (-2.06%)
At close: Mar 28, 2024, 4:00 PM
1.920
+0.020 (1.05%)
After-hours: Mar 28, 2024, 6:17 PM EDT
-2.06%
Market Cap 121.45M
Revenue (ttm) 16.66M
Net Income (ttm) -86.28M
Shares Out 64.77M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 377,781
Open 1.970
Previous Close 1.940
Day's Range 1.870 - 2.000
52-Week Range 1.455 - 5.650
Beta 1.63
Analysts Hold
Price Target 7.00 (+268.42%)
Earnings Date Feb 27, 2023

About SEER

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratori... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 147
Stock Exchange NASDAQ
Ticker Symbol SEER
Full Company Profile

Financial Performance

In 2023, Seer, Inc.'s revenue was $16.66 million, an increase of 7.54% compared to the previous year's $15.49 million. Losses were -$86.28 million, -7.20% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SEER stock is "Hold" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(268.42% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data

4 weeks ago - GlobeNewsWire

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

5 weeks ago - GlobeNewsWire

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies

7 weeks ago - GlobeNewsWire

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

2 months ago - GlobeNewsWire

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

3 months ago - GlobeNewsWire

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company man...

5 months ago - GlobeNewsWire

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics

5 months ago - GlobeNewsWire

Seer Reports Third Quarter 2023 Financial Results

Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence Expanded access to the Proteograph™ Product Suite through t...

5 months ago - GlobeNewsWire

Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program

Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services Panome Bio adds deep, unbiased proteomics to their proprietary metabolom...

5 months ago - GlobeNewsWire

Seer to Report Third Quarter 2023 Financial Results on November 7, 2023

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report...

5 months ago - GlobeNewsWire

Seer to Participate in Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management...

7 months ago - GlobeNewsWire

Seer Reports Second Quarter 2023 Financial Results

Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies

8 months ago - GlobeNewsWire

Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

8 months ago - GlobeNewsWire

Seer to Report Second Quarter 2023 Financial Results on August 8, 2023

REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

9 months ago - GlobeNewsWire

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center

Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific commu...

10 months ago - GlobeNewsWire

Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies

Seer's Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer's Proteograph X...

10 months ago - GlobeNewsWire

Seer Reports First Quarter 2023 Financial Results

Grew revenue 22% year-over-year with continued growth in installed base and an increasing number of customer presentations and publications REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Seer,...

11 months ago - GlobeNewsWire

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will repor...

1 year ago - GlobeNewsWire

Seer's Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression

Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Peptide-level insights from deep, un...

1 year ago - GlobeNewsWire

Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook

Grew revenue 134% and increased instruments shipped 129% year over year Grew revenue 134% and increased instruments shipped 129% year over year

1 year ago - GlobeNewsWire

Seer to Present at the Cowen 43rd Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

1 year ago - GlobeNewsWire

Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report...

1 year ago - GlobeNewsWire

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

1 year ago - GlobeNewsWire

DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS

Creates a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis to support drug and diagnostic development HUNTSVILLE, Ala. , Dec. 14, 2022 /PRN...

Other symbols: OLK
1 year ago - PRNewsWire

Seer's Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist

Annual award from The Scientist celebrates transformative products like Seer's Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible Annual award from The Scientist celebrate...

1 year ago - GlobeNewsWire